Amicus Therapeutics — Technical Presentation (February 2020)
41 slides from Amicus Therapeutics's technical presentation, Feb 12, 2020
Slide 1: Perspectives on Pompe: Progress, Persistence and Passion
Perspectives on Pompe: Progress, Persistence and Passion February 12, 2020
Slide 2: Forward-Looking Statements
2 Forward-Looking Statements This presentation contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 relating to scientific theories regarding our product candidate and to preclinical and clinical development of our product candidates. The i
Slide 3: Importance of Properly Glycosylated rhGAA for Treating Pompe Disease
Importance of Properly Glycosylated rhGAA for Treating Pompe Disease Hung Do, Ph.D., Chief Science Officer “We encourage and embrace constant innovation” - Amicus Belief Statement
Slide 4: Carbohydrates Are Critical for Sorting and Transporting Proteins
Importance of Properly Glycosylated rhGAA for Treating Pompe Disease 4 Carbohydrates Are Critical for Sorting and Transporting Proteins From Within and Outside of Cells • ALL lysosomal, ER, Golgi, secretory (e.g., antibodies and clotting factors), membrane, and peroxisomal and most mitochondrial pro
Slide 5: N-Linked Carbohydrate Processing is Complicated and Difficult to Regulate
Importance of Properly Glycosylated rhGAA for Treating Pompe Disease 5 N-Linked Carbohydrate Processing is Complicated and Extremely Difficult to Regulate in Production Cells • Vast majority of proteins synthesized in ER are modified with asparagine (N)-linked carbohydrates (N-glycans) during protei
Slide 6: GAA Is Inherently Poorly Phosphorylated in Cells
Importance of Properly Glycosylated rhGAA for Treating Pompe Disease 6 GAA Is Inherently Poorly Phosphorylated in Cells Relative Binding to M6P Receptor Liu et al., 2017 Alglucosidase alfa • rhGAA is among a group of lysosomal enzymes that are inherently poorly phosphorylated – Phosphotransferase is
Slide 7: Only Tiny Amounts of rhGAA Reach Intended Muscles
Importance of Properly Glycosylated rhGAA for Treating Pompe Disease 7 Only Tiny Amounts of rhGAA from Circulation Actually Reach Intended Muscles Do et al., 2019 Biodistribution of rhGAA ERT to intended muscles is very poor which necessitates highly efficient cellular uptake mechanisms Endothelial
Slide 8: N-Glycan Structures Dictate Cellular Uptake of ERTs
Importance of Properly Glycosylated rhGAA for Treating Pompe Disease 8 N-Glycan Structures Dictate Cellular Uptake of ERTs in Target Cells Adapted from Tong et al., 1989 Soluble lysosomal enzymes require M6P for cellular uptake; bis-phosphorylated N-glycans would be needed for uptake at low enzyme c
Slide 9: ATB200: Optimized rhGAA with Higher M6P Receptor Binding Affinity
Importance of Properly Glycosylated rhGAA for Treating Pompe Disease 9 ATB200: Amicus’ Optimized rhGAA ERT Has Substantially Higher Binding Affinity to M6P Receptor for Improved Cellular Uptake M6P Receptor Chromatography ATB200: Amicus’ Next-Generation rhGAA ERT for Pompe Disease Alglucosidase alfa
Slide 10: Enhanced Cellular Uptake of AT-GAA Improves Glycogen Reduction
Importance of Properly Glycosylated rhGAA for Treating Pompe Disease 10 Enhanced Cellular Uptake of AT-GAA Leads to Much Improved Glycogen Reduction and Reversal of Muscle Pathology in Preclinical Models - Xu et al., 2019 Myofiber Structure Analysis by SHG/2PEF Microscopy ERT concentration range in
Slide 11: NeoGAA Therapeutics
NeoGAA Therapeutics
Slide 12: Key Reported Features of NeoGAA
12 Key Reported Features of NeoGAA Zhu et al., 2009 Chemical Structure of NeoGlycan Schematic of Chemical Conjugation Approach Zhu et al., 2009 • NeoGAA approach relies upon the chemical conjugation of synthetic M6P-bearing carbohydrate structure (Neo- glycan) onto existing N-glycans of alglucosidas
Slide 13: NeoGAA's Approach for Increasing M6P Levels on Alglucosidase Alfa
13 Neo-GAA’s Approach for Increasing M6P Levels on Alglucosidase Alfa by Attaching Synthetic Carbohydrate Structure - Zhu et al. 2009 Resultant stable oxime chemical bond is unnatural and cannot be hydrolyzed by enzymes within cells which would negatively impact GAA processing Chemically oxidized te
Slide 14: GAA Processing in Lysosomes is Required for Optimal Glycogen Hydrolysis
14 GAA Processing in Lysosomes is Required for Optimal Glycogen Hydrolysis Moreland et al. (2012) Gene 491 25-30 Wisselaar et al. (1993) J. Biol. Chem. 268(3) 2223-2231
Slide 15: Fully Processed GAA and Debranching Enzyme Required for Glycogen Catabolism
15 Fully Processed GAA and Debranching Enzyme Are Required for Efficient Glycogen Catabolism in Lysosomes Glycogen debrancher enzyme (Cori-Forbes disease; GSD type III) acid α-glucosidase (GAA) Public domain images (Pompe disease; GSD type II) from WikiMedia Commons Glycogen • Glycogen is a large po
Slide 16: ATB200-02 Clinical Outcome in Naive Patients - Behind the Data
ATB200-02 Clinical Outcome in 4 Naive Patients - Behind the Data Dr Drago Bratkovic MBBS FRACP Women’s and Children’s Hospital, Adelaide, South Australia
Slide 17: Overview
Overview • ATB200-02 Trial Protocol Overview • Combined Data • Individualised Data of Naive Patients • 6MWT, FVC, GSGC (Gait, Stair, Gower's, Chair) • Patient Reported Outcomes - Fatigue Severity Score • Clinical Description • Summary
Slide 18: ATB200-02 Study Design (NCT02675465)
ATB200-02 Study Design (NCT02675465) « Phase 1/2 study to evaluate safety, tolerability, PK, PD, and efficacy of ATB200/AT2221 in adults with Pompe disease? 18-Week Primary Treatment Period With Long-Term Extension Stage 1 (6 wks) age 2 (12 wks { : (2 yrs, ongoing) ATB200 single-dose 0 2 N f 5 mg/kg
Slide 19: Baseline Characteristics
Baseline Characteristics Cohort 1 Cohort 2 Cohort 3 ERT-Switch ERT-Switch? ERT-Naive _ERT-Switct (2-6 yrs on ERT) | Non-ambulatory (27 yrs on ERT) n=11 n=6 n=5 n=6 Age, years, mean (min, max) | 49.4 (28, 66) 41.5 (18, 57) 49.4 (24, 65) Sex, M:F | 9:2 4:2 1:4 40.8 (20, 65) 2:4 Time on alglucosidase a
Slide 20: 6-Minute Walk Test
6-Minute Walk Test Cohorts 1 and 3 Baseline (meters) 397.2 (96.8) | 107] +23.9(52.2) | 108] +42.2 (46.5) ERT-Naive 399.5 (83.5) 5 +41.8 (29.4) 5 +63.1 (29.1) +60.7 (36.5) | 5 | = 6MWT increased in 7/10, 9/10, and 8/9 ERT-switch patients at Months 6, 12, and 24, respectively ™ 6MWT increased in 5/5,
Slide 21: Sitting Forced Vital Capacity (FVC, % Predicted)
Sitting Forced Vital Capacity (FVC, % Predicted) 52.6 (14.7) -1.2 (4.0) -3.0 (6.0) +0.9 (4.9) 53.2 (20.1) +4.4 (5.6) +4.6 (8.8) esta ™ FVC was stable or increased in 5/8 ERT-switch patients at Month 24 (2-6 yrs on ERT); MIP was stable and MEP increased ™ FVC was stable or increased in 5/5 ERT-naive
Slide 22: GSGC Combination Measure
GSGC Combination of: • Gait (G) • Climbing stairs (S) • Gower’s maneuver (G) • Arising from a chair (C) Quality of the activity is scored by an observer and timed Measure of day to day activities Scored as the sum of the scores • Lower the better • Maximum 27, Minimum 4
Slide 23: GSGC Score Before and After ERT
sec ° TF Gait Stairs Gower Chair Score eS ee a) ne 34 FIGURE 1. Results of the GSGC score before and after 1 year of ERT. TO = baseline. T12 = 12 months. The functional tests are timed in seconds, while the score expresses the sum of points of each test. Asterisks show significance P < 0.05. oNna@ a
Slide 24: Timed Motor Function Tests
Timed Motor Function Tests Baseline, Change From Baseline, mean (SD mean(SD) | Month6 | Month 12 | Month 24 EE eee ee Timed UpandGo, sec. 10.5(6.6) | -1.8(3.5) | -1.5(2.8) | —_-0.7 (2.5) GSGC Score | 12.6(4.8) | +0.1 (3.9) | -0.3(4.1) | 0.1 (5.2) ones Timed UpandGo, sec. 9.4(2.3) | -1.0(1.1) | -0.3
Slide 25: Fatigue Severity Scale
Fatigue Severity Scale 7 point scale 9 questions Range 7 to 63 • Sometimes expressed as a mean of the 9 scores (1-7) • Lower the Better Validated and used in a number of neurological disorders including Pompe disease
Slide 26: Fatigue Severity Scale Scores During ERT
During ER’ Fatigue severity Scale Scores 2 ° To © ° 4 J °oo8 oo, ° ° ° gic ° 1 ° $ [29% 00 @ 8 7 6 8 4 3 2 -1StartERT1 2 3 4 5 6 7 8 Follow-up duration in years Fig. 1. The figure shows the change in Fatigue Severity-Scale scores (FSS) before and after the start of enzyme replacement therapy (ERT).
Slide 27: Fatigue Severity Scale
Fatigue Severity Scale Patient-Reported Outcome (PRO) Instrument Cohort Max score=63 -8.0 (10.7) -8.0 (6.5) 10°| -4.1 (8.6) |e +2.0(7.5) | 5°} -12.5 (10.0) 45.6 (14.7) | 5° ERT-Naive 39.2 (12.7) 5 | 5.2(11.7) | 5 | -7.2(75) | 5 ERT=enzyme replacement therapy; SD=standard deviation. 1. Grace J et al.
Slide 28: Subject: Early 40s and mother of pre-teen children
Subject 1 Early 40s and mother of 2 pre teen children Diagnosed 4 years prior to ATB200-02 Noticing gradual decline in motor function especially in last few Change at Change at Baseline years 12 months 24 months Unable to safely run and requiring support to get up stairs 6MWT (m) 480 94.6 78.2 Not o
Slide 29: Subject: Mid 20s living at home with her mother
Subject 2 Mid 20’s and living at home with her mother Diagnosed 5 years prior to study with issues getting up from a chair and increasing headaches. GP noticed a positive Gower’s Change at Change at Baseline sign 12 months 24 months Significant respiratory compromise 6MWT (m) 384.1 78.9 106.9 • BiPA
Slide 30: Subject: Early 60s
Subject 3 Early 60’s Symptomatic from 40’s similar to her sister who was diagnosed at this age. Change at Change at Baseline Put off testing until she started having problems with her sleep 12 months 24 months and headaches 6MWT (m) 267.3 30.8 20.7 Relatively intact upper limb strength BiPAP overnig
Slide 31: Subject: Female, Mid 60s
Subject 4 Female, Mid 60’s Initially diagnosed with a limb-girdle muscular dystrophy in late 50’s. Eventually tested for Pompe disease. Change at Change at Baseline Unable to pick up grandchildren and trouble keeping up with her 12 months 24 months husband on walks 6MWT (m) 406.3 33.4 26.4 No BiPAP
Slide 32: Compassionate Access Single Case Review
Compassionate Access Single Case Review John F. Crowley, Chairman and Chief Executive Officer Markus Peceny, Medical Director
Slide 33: Expanded Access Program (EAP) Request
Compassionate Access Single Case Review 33 Expanded Access Program (EAP) Request Amicus received the compassionate use request on 24th September 2019 “This is a request for emergency early access to your new acid glucosidase preparation that has a higher amount of mannose-6-phosphate residues and is
Slide 34: EAP Request
Compassionate Access Single Case Review 34 EAP Request
Slide 35: A Message from the Parents
Compassionate Access Single Case Review 35 EAP Request A Message from the Parents
Slide 36: EAP Request Granted
Compassionate Access Single Case Review 36 EAP Request Granted Amicus early access granted on 4th October 2019 “God bless you all for your incredible work and your positive decision. I am sure you have saved a life here!!! THANK YOU!!!!!!!!!!!!!!!!!!!!!!!!!! I am in pediatric metabolic diseases for
Slide 37: Diagnosis, Treatment History and Initiation of AT-GAA
Compassionate Access Single Case Review 37 Diagnosis, Treatment History and Initiation of AT-GAA IOPD CRIM-negative infant initiated treatment on alglucosidase alfa at 7 months of age; experienced decline in cardiac function even after going to 40mg/week. Improved on AT-GAA • Diagnosis of IOPD Jan 2
Slide 38: Clinical Response to ERT measured via Fractional Shortening
Compassionate Access Single Case Review 38 Clinical Response to ERT measured via Fractional Shortening (FS) After switching to AT-GAA the fractional shortening improved from unmeasurable to a value of 30-36% after only 2-3 months; motor function improved and supplemental oxygen no longer required
Slide 39: Prof. Marquart's Video Testimony
Compassionate Access Single Case Review 39 Prof. Marquart’s Video Testimony
Slide 40: Parent Video Testimony
Compassionate Access Single Case Review 40 Parent Video Testimony
Slide 41: Thank You
Thank You
Amicus Therapeutics — Technical Presentation (February 2020) on 6ix